SCHEMBL3076700

SCHEMBL3076700

Cc1nc(-c2ccc(OCCCCl)cc2)sc1C(=O)N1CCC(F)(F)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.55
CNR1 P21554 1/20 0.47
TARBP2 Q15633 1/20 0.47
ALDH1A1 P00352 4/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PPARD Q03181 3/20 0.43
PPARA Q07869 3/20 0.43
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
MAPT P10636 2/20 0.41
THRA P10827 1/20 0.39
THRB P10828 1/20 0.39
RAB9A P51151 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
HTR2C P28335 3/20 0.39
GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3074369 0.86 HRH3 (0.71) HRH3CNR1TARBP2ALDH1A1PPARD
SCHEMBL3079950 0.84 HRH3 (0.79) HRH3
SCHEMBL3071302 0.84 HRH3 (0.79) HRH3
SCHEMBL3066463 0.84 HRH3 (0.79) HRH3
SCHEMBL3071111 0.79 TARBP2 (0.70) HRH3TARBP2ALDH1A1MEN1KMT2A
SCHEMBL3402560 0.77 HRH3 (0.54) HRH3CNR1TARBP2ALDH1A1MEN1
SCHEMBL3069938 0.77 TARBP2 (0.54) HRH3TARBP2ALDH1A1MEN1KMT2A
SCHEMBL3586967 0.76 PPARD (0.37) HRH3ALDH1A1MEN1KMT2APPARD
SCHEMBL3402146 0.75 TARBP2 (0.53) HRH3CNR1TARBP2ALDH1A1MEN1
SCHEMBL3403473 0.73 HRH3 (0.58) HRH3CNR1TARBP2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR HRH3 4/4885CNR1 58/4885TARBP2 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.